Skip to main content

Table 1 Baseline characteristics of the study population (n = 172)

From: Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort

Characteristic 
Women, no./total (%)139/172 (80.8)
Age, mean ± SD, years49.5 ± 12.8
Smoking status, no. (%)
 Current smoking46 (26.7)
 Past smoking42 (24.4)
 Never smoked93 (54.1)
DAS28, no. (%)
 Low disease activity1 (0.6)
 Moderate disease activity70 (40.7)
 High disease activity101 (58.7)
Tender joint count, mean ± SD9 ± 5.5
Swollen joint count, mean ± SD11.7 ± 7.1
HAQ-DI, mean ± SD1.1 ± 0.7
ESR (mm/h), mean ± SD25.2 ± 23.6
CRP (mg/dl), mean ± SD23.2 ± 42.8
mTSS, mean ± SD5.5 ± 7.0
Treatment, no. (%)
 Methotrexate98 (57)
 Leflunomide12 (7)
 Sulfasalazine22 (12.8)
 Hydroxychloroquine37 (21.5)
 Cyclophosphamide1 (0.6)
 Biologic DMARD2 (1.2)
  1. CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, DMARD disease-modifying antirheumatic drug, ESR erythrocyte sedimentation rate, HAQ Health Assessment Questionnaire-Disability Index, mTSS van der Heijde-modified total Sharp score